Margarita Lamothe, MD
Infectious Disease · Memphis, TNNPI 1306887187
Payments from drug & device makers
Across 677 payments — averaging $17.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
- Viiv Healthcare Company$2K
- AbbVie$1K
- Merck$1K
- Insmed, Inc.$1K
- La Jolla Pharmaceutical Company$816
- plus $3K from 20 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 140 | $2,214 |
| Viiv Healthcare Company | 115 | $1,687 |
| AbbVie(2 entities) | 97 | $1,341 |
| Merck | 75 | $1,249 |
| Insmed, Inc. | 45 | $1,014 |
| La Jolla Pharmaceutical Company | 46 | $816 |
| Cumberland Pharmaceuticals, Inc. | 10 | $560 |
| Pfizer | 25 | $434 |
| Theratechnologies Inc. | 22 | $371 |
| Johnson & Johnson | 24 | $335 |
| Tetraphase Pharmaceuticals, Inc. | 20 | $330 |
| Melinta Therapeutics, LLC | 16 | $237 |
| Astellas Pharma US Inc | 7 | $220 |
| Biotissue Holdings Inc. | 3 | $147 |
| Shionogi Inc | 6 | $115 |
| Ferring Pharmaceuticals Inc. | 5 | $106 |
| Mayne Pharma Commercial LLC | 5 | $74 |
| Paratek Pharmaceuticals, Inc. | 4 | $66 |
| AstraZeneca | 3 | $54 |
| EMD Serono, Inc. | 3 | $54 |
| Triad Life Sciences Inc. | 1 | $37 |
| Convatec Inc. | 1 | $25 |
| Dynavax Technologies Corporation | 1 | $20 |
| Nabriva Therapeutics, PLC | 1 | $16 |
| Medela LLC | 1 | $13 |
| Mylan Institutional Inc. | 1 | $12 |
How this compares
$11,548 in reported general payments places this provider in the 85th percentile of 156 infectious disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Memphis
- Michael GelfandMemphis$486K
- Kerry ClevelandMemphis$427K
- Nathan SummersMemphis$80K
- Stephen ThrelkeldMemphis$27K
- Imad OmerMemphis$22K
- Daniel MurrellMemphis$12K
- James DaleMemphis$8K
- Michael ThrelkeldMemphis$5K
- Kristie NowakMemphis$2K
- Shirin MazumderMemphis$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.